Suppr超能文献

一项基于人群的重症肌无力流行病学研究的系统综述。

A systematic review of population based epidemiological studies in Myasthenia Gravis.

机构信息

Department of Neurology, Royal Victoria Hospital, Belfast, Northern Ireland, UK.

出版信息

BMC Neurol. 2010 Jun 18;10:46. doi: 10.1186/1471-2377-10-46.

Abstract

BACKGROUND

The aim was to collate all myasthenia gravis (MG) epidemiological studies including AChR MG and MuSK MG specific studies. To synthesize data on incidence rate (IR), prevalence rate (PR) and mortality rate (MR) of the condition and investigate the influence of environmental and technical factors on any trends or variation observed.

METHODS

Studies were identified using multiple sources and meta-analysis performed to calculate pooled estimates for IR, PR and MR.

RESULTS

55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years. For All MG estimated pooled IR (eIR): 5.3 per million person-years (C.I.:4.4, 6.1), range: 1.7 to 21.3; estimated pooled PR: 77.7 per million persons (C.I.:64.0, 94.3), range 15 to 179; MR range 0.1 to 0.9 per millions person-years. AChR MG eIR: 7.3 (C.I.:5.5, 7.8), range: 4.3 to 18.0; MuSK MG IR range: 0.1 to 0.32. However marked variation persisted between populations studied with similar methodology and in similar areas.

CONCLUSIONS

We report marked variation in observed frequencies of MG. We show evidence of increasing frequency of MG with year of study and improved study quality. This probably reflects improved case ascertainment. But other factors must also influence disease onset resulting in the observed variation in IR across geographically and genetically similar populations.

摘要

背景

本研究旨在整理所有重症肌无力(MG)流行病学研究,包括乙酰胆碱受体(AChR)MG 和肌肉特异性酪氨酸激酶(MuSK)MG 特异性研究。旨在综合发病率(IR)、患病率(PR)和死亡率(MR)数据,并调查环境和技术因素对任何观察到的趋势或变化的影响。

方法

使用多种来源识别研究,并进行荟萃分析以计算 IR、PR 和 MR 的汇总估计值。

结果

纳入了 1950 年至 2007 年期间进行的 55 项研究,代表了 17 亿人口年。所有 MG 的估计汇总发病率(eIR):5.3/百万人年(置信区间:4.4,6.1),范围:1.7 至 21.3;估计汇总患病率(PR):77.7/百万人(置信区间:64.0,94.3),范围 15 至 179;MR 范围为 0.1 至 0.9/百万人年。AChR MG eIR:7.3(置信区间:5.5,7.8),范围:4.3 至 18.0;MuSK MG IR 范围:0.1 至 0.32。但是,具有相似方法学和相似地区的研究人群之间仍然存在明显的差异。

结论

我们报告了 MG 观察到的频率存在明显差异。我们有证据表明,随着研究年份的增加和研究质量的提高,MG 的频率也在增加。这可能反映了更好的病例发现。但是,其他因素也必须影响疾病的发生,导致在地理和遗传上相似的人群中观察到的 IR 存在差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/835a/2905354/31a98898440d/1471-2377-10-46-1.jpg

相似文献

1
A systematic review of population based epidemiological studies in Myasthenia Gravis.
BMC Neurol. 2010 Jun 18;10:46. doi: 10.1186/1471-2377-10-46.
2
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
3
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306. doi: 10.1002/14651858.CD013306.pub2.
5
Interventions for emergency contraception.
Cochrane Database Syst Rev. 2017 Aug 2;8(8):CD001324. doi: 10.1002/14651858.CD001324.pub5.
7
Sertindole for schizophrenia.
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
8
Electronic cigarettes for smoking cessation.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216. doi: 10.1002/14651858.CD010216.pub7.
9
Electronic cigarettes for smoking cessation.
Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub6.

引用本文的文献

1
Practitioner's perception of myasthenia gravis management recommendations in clinical practice: a cross-sectional survey study.
Ther Adv Chronic Dis. 2025 Sep 11;16:20406223251368063. doi: 10.1177/20406223251368063. eCollection 2025.
3
FcRn inhibitors for myasthenia gravis.
Cochrane Database Syst Rev. 2025 Aug 22;8(8):CD016097. doi: 10.1002/14651858.CD016097.
5
Predicting achievement of clinical goals using machine learning in myasthenia gravis.
PLoS One. 2025 Aug 14;20(8):e0330044. doi: 10.1371/journal.pone.0330044. eCollection 2025.
6
7
Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management.
Neurol Ther. 2025 Aug 5. doi: 10.1007/s40120-025-00796-w.
9
Outcomes of myasthenia gravis patients admitted to the Intensive Care Unit: Experience from a tertiary care center in Saudi Arabia.
PLoS One. 2025 Jul 28;20(7):e0328648. doi: 10.1371/journal.pone.0328648. eCollection 2025.
10
Circadian rhythm genes and immune cell infiltration in myasthenia gravis: A comprehensive analysis.
PLoS One. 2025 Jul 7;20(7):e0327829. doi: 10.1371/journal.pone.0327829. eCollection 2025.

本文引用的文献

1
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.
Lancet Neurol. 2009 May;8(5):475-90. doi: 10.1016/S1474-4422(09)70063-8.
2
Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece.
Eur J Neurol. 2009 Aug;16(8):925-30. doi: 10.1111/j.1468-1331.2009.02624.x. Epub 2009 Apr 3.
3
Myasthenia gravis seronegative for acetylcholine receptor antibodies.
Ann N Y Acad Sci. 2008;1132:84-92. doi: 10.1196/annals.1405.020.
4
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
Brain. 2008 Jul;131(Pt 7):1940-52. doi: 10.1093/brain/awn092. Epub 2008 May 31.
6
Epidemiology of autoimmune diseases in Denmark.
J Autoimmun. 2007 Aug;29(1):1-9. doi: 10.1016/j.jaut.2007.05.002. Epub 2007 Jun 19.
7
Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.
J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):417-8. doi: 10.1136/jnnp.2006.102517. Epub 2006 Oct 20.
8
[Population-based study of myasthenia in Moscow region].
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(5):52-5.
9
Epidemiological study of muscular disorders in Assiut, Egypt.
Neuroepidemiology. 2005;25(4):205-11. doi: 10.1159/000088674. Epub 2005 Oct 4.
10
Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis.
Neurology. 2005 Sep 27;65(6):928-30. doi: 10.1212/01.wnl.0000176067.32186.a3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验